-       Report 
- May 2021
-  50 Pages 
- China 
   From       €2326EUR$2,600USD£2,046GBP 
          -       Report 
- March 2024
-  200 Pages 
- Global 
   From       €3712EUR$4,150USD£3,265GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
             -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- May 2024
-  140 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- March 2024
-  238 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- February 2024
-  120 Pages 
- Asia Pacific 
   From       €3542EUR$3,960USD£3,116GBP 
      €4428EUR$4,950USD£3,895GBP 
            -       Drug Pipelines 
- February 2022
-  74 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
       
       The Urological Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat urological disorders. These disorders include urinary tract infections, bladder control issues, kidney stones, prostate cancer, and erectile dysfunction. Companies in this market develop and market drugs that can help to reduce the symptoms of these disorders, as well as provide treatments for them.
Some of the major players in the Urological Disorders    Drugs market include Pfizer, Merck, AstraZeneca, GlaxoSmithKline, and Sanofi. These companies have a wide range of products that are used to treat urological disorders, including antibiotics, antifungals, and anti-inflammatory drugs. Additionally, they have developed drugs that can help to reduce the symptoms of these disorders, such as pain relievers and muscle relaxants. Show Less   Read more